Astrazeneca Pharmaceuticals LP

Wilmington, DE

UEI
E5K2ZJ8CTJH4
CAGE
36WK2
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Foreign Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
  • Astrazeneca Pharmaceuticals LP E5K2ZJ8CTJH4
SAM.gov registration date
Physical address
1800 Concord Pike, Wilmington, DE 19803, USA
Website
astrazeneca-us.com
Founded
1999
Employees
50K-100K
Estimated annual revenue
$10B+
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Astrazeneca Pharmaceuticals LP's 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
8511731821 ! Other medical Contract · SPE2D026F0023 Medical Supply Chain $500
8510989335 ! Other medical Contract · SPE2D025F0051 Medical Supply Chain $500
8510242912 ! Other medical Contract · SPE2D024F0018 Medical Supply Chain $500
Purchase of influenza vaccine supplies for nssc customers. Contract · 75H71123P00482 Indian Health Service $0
8509493425 ! Other medical Contract · SPE2D023F0010 Medical Supply Chain $500

About Astrazeneca Pharmaceuticals LP

Astrazeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer headquartered in Wilmington, Delaware, supplies vaccines, pharmaceutical preparations, and medical countermeasures to federal agencies as a prime contractor on full-and-open contracts with no set-aside designations. The company operates across 221 recent prime awards (100% of its federal footprint) valued at $17.45 billion in combined potential value, with $3.1 billion obligated to date.

Astrazeneca's federal capability portfolio centers on seasonal influenza vaccines (pediatric and adult formulations), prescription pharmaceuticals for veteran and federal employee populations, and medical supplies distributed through federal health agencies. Representative work includes a $75.52 million CDC Indefinite Delivery Contract for pediatric flu vaccines covering the 2022–2023 season (awarded January 5, 2022, through February 28, 2023); a $913.9 million single-award VA contract for acalabrutinib tablets (100 mg BTK inhibitor) serving the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service (awarded June 24, 2024, through June 23, 2027, with four one-year options, second option exercised); and a $58.53 million CDC multiple-award contract for pediatric flu vaccines for the 2023–2024 season. Recent 2025 awards include a $32.01 million CDC pediatric flu vaccine contract and a $9.3 million CDC adult flu vaccine contract, both through February 28, 2027. Astrazeneca also received two National Institute on Drug Abuse cooperative agreements as research recipient for development of AZD4041/BPN-19302, a selective orexin-1 receptor antagonist for opioid use disorder treatment, in collaboration with Eolas Therapeutics and the NIH Blueprint Neurotherapeutics Network (awarded August 15, 2021; one agreement completed March 31, 2024, the second through February 28, 2025).

Customer concentration heavily favors the Department of Veterans Affairs Veterans Integrated Service Network 12, which anchors $11.86 billion (68% of combined potential value) across two awards, primarily the acalabrutinib contract. The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense holds $2.79 billion across five awards; the VA National Acquisition Center holds $1.66 billion across four awards; and CDC Pittsburgh holds $986.4 million across twenty awards. These five customers account for all tracked potential value. Award volume has remained modest and flat — five awards in 2021, six in 2022, two in 2023, six in 2024, and three in 2025 — with minimal near-term recompete exposure (one award of $500 completing in the next twenty-four months).

Astrazeneca's top parent vehicles are the Indefinite Delivery Contract SPE2D017D0002 (ten task orders, $5 thousand combined value) and several Federal Supply Schedules (V797P5274X, V797P5853N, V797P5343X combined). Award categories concentrate in Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (148 awards, primarily the vaccine supply work), Pharmaceutical Preparation Manufacturing (40 awards), and Medicinal and Botanical Manufacturing (11 awards), with corresponding PSC codes reflecting Drugs and Biologicals (45 awards) and Medical and Surgical Instruments, Equipment, and Supplies (154 awards).

The company's named subsidiary is Medimmune LLC, a for-profit organization that develops and manufactures vaccines and immunotherapeutics for federal health agencies. Astrazeneca competes on full-and-open, unrestricted procurements reflective of its large business status and does not participate in set-aside categories.

Contract vehicles

Quick answers

What is Astrazeneca Pharmaceuticals LP's UEI?

Astrazeneca Pharmaceuticals LP's Unique Entity ID (UEI) in SAM.gov is E5K2ZJ8CTJH4.

What is Astrazeneca Pharmaceuticals LP's CAGE code?

Astrazeneca Pharmaceuticals LP's CAGE code is 36WK2.

What is Astrazeneca Pharmaceuticals LP's primary NAICS code?

Astrazeneca Pharmaceuticals LP's primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).

Where is Astrazeneca Pharmaceuticals LP located?

Astrazeneca Pharmaceuticals LP's physical address in SAM.gov is 1800 Concord Pike, Wilmington, DE 19803, USA.

Is Astrazeneca Pharmaceuticals LP registered in SAM.gov?

Yes. Astrazeneca Pharmaceuticals LP's SAM.gov registration is active through August 18, 2027.

Which contract vehicles does Astrazeneca Pharmaceuticals LP hold?

Astrazeneca Pharmaceuticals LP holds a place on 1 federal contract vehicle: FSS-61-IB.

What is Astrazeneca Pharmaceuticals LP's most recent federal award?

Astrazeneca Pharmaceuticals LP's most recent federal contract award is 8511731821 ! Other medical (SPE2D026F0023), from Medical Supply Chain, on November 3, 2025.

On GovTribe

See Astrazeneca Pharmaceuticals LP's full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors